FDA so­lic­its in­dus­try in­put for OND pol­i­cy pri­or­i­ties

A Fri­day FDA no­tice is so­lic­it­ing pol­i­cy sug­ges­tions from the in­dus­try that re­view staff at the FDA’s Of­fice of New Drugs (OND) can im­ple­ment in the near fu­ture.

To hear from in­dus­try on “spe­cif­ic, ac­tion­able pol­i­cy sug­ges­tions that could be im­ple­ment­ed in the near-term,” the FDA is so­lic­it­ing pre­sen­ta­tions for dis­cus­sions at a pub­lic meet­ing set via the Fed­er­al Reg­is­ter no­tice as well as invit­ing com­ments on the top­ics that the no­tice dis­cuss­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER